.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Federal Trade Commission
Cipla
Johnson and Johnson
Baxter
Fish and Richardson
Express Scripts
QuintilesIMS
AstraZeneca
Queensland Health

Generated: September 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,863,287 protect, and when does it expire?


Patent ► Subscribe protects ADVIL ALLERGY SINUS and is included in one NDA.

This patent has thirty-three patent family members in eighteen countries.

Summary for Patent: ► Subscribe

Title:Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
Abstract: The present invention is directed to a pharmaceutical composition and method for the treatment of rhinitis and cold-like symptoms which includes a non-steroidal anti-inflammatory drug (NSAID), a decongestant, and an antihistamine. It has been found that an NSAID enhances the activity of a decongestant and an anti-histamine, thus permitting a reduction in either or both in administration of separate dosage forms. The same enhancement can also occur with an anti-tussitive. Thus, the effective amount of the decongestant or the antihistamine or both is less than about 75% of an amount present in an approved dose of the decongestant or the antihistamine, or both, relative to an amount of the NSAID corresponding to about 100% of the amount present in a normal strength dosage form of the NSAID.
Inventor(s): Berlin; Roger G. (Mendham, NJ)
Assignee: Wyeth LLC (Madison, NJ)
Application Number:10/740,386
Patent Claim Types:
see list of patent claims
Dosage form; Formulation; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pfizer
ADVIL ALLERGY SINUS
chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride
TABLET;ORAL021441-001Dec 19, 2002OTCYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI313598► Subscribe
Taiwan200413004► Subscribe
Russian Federation2322262► Subscribe
Russian Federation2005122403► Subscribe
Portugal1572206► Subscribe
Peru10722008► Subscribe
Peru09732004► Subscribe
New Zealand552030► Subscribe
New Zealand540289► Subscribe
MexicoPA06013919► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Harvard Business School
Dow
AstraZeneca
Boehringer Ingelheim
Farmers Insurance
Julphar
McKinsey
US Department of Justice
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot